CN115160402A - 结晶盐形式 - Google Patents

结晶盐形式 Download PDF

Info

Publication number
CN115160402A
CN115160402A CN202210620260.3A CN202210620260A CN115160402A CN 115160402 A CN115160402 A CN 115160402A CN 202210620260 A CN202210620260 A CN 202210620260A CN 115160402 A CN115160402 A CN 115160402A
Authority
CN
China
Prior art keywords
crystalline form
compound
xrpd
characteristic peaks
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210620260.3A
Other languages
English (en)
Chinese (zh)
Inventor
S.M.邓肯
M.P.雷蒙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stealth Biotherapeutics Corp
Original Assignee
Stealth Biotherapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Biotherapeutics Corp filed Critical Stealth Biotherapeutics Corp
Publication of CN115160402A publication Critical patent/CN115160402A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C07C55/07—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/08—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202210620260.3A 2016-03-11 2017-03-10 结晶盐形式 Pending CN115160402A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662307095P 2016-03-11 2016-03-11
US62/307095 2016-03-11
PCT/US2017/021790 WO2017156403A1 (en) 2016-03-11 2017-03-10 Crystalline salt forms
CN201780029335.8A CN109476700A (zh) 2016-03-11 2017-03-10 结晶盐形式

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780029335.8A Division CN109476700A (zh) 2016-03-11 2017-03-10 结晶盐形式

Publications (1)

Publication Number Publication Date
CN115160402A true CN115160402A (zh) 2022-10-11

Family

ID=59789873

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210620260.3A Pending CN115160402A (zh) 2016-03-11 2017-03-10 结晶盐形式
CN201780029335.8A Pending CN109476700A (zh) 2016-03-11 2017-03-10 结晶盐形式

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780029335.8A Pending CN109476700A (zh) 2016-03-11 2017-03-10 结晶盐形式

Country Status (6)

Country Link
US (4) US10683326B2 (https=)
EP (1) EP3426675B1 (https=)
JP (1) JP7038675B2 (https=)
CN (2) CN115160402A (https=)
CA (1) CA3017359A1 (https=)
WO (1) WO2017156403A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3017359A1 (en) 2016-03-11 2017-09-14 Scott M. Duncan Crystalline salt forms
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
KR20250010134A (ko) 2018-04-02 2025-01-20 스텔스 바이오테라퓨틱스 인코포레이티드 엘라미프레티드의 합성에 유용한 결정질 디펩티드

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103933542A (zh) * 2009-03-20 2014-07-23 通用医疗公司以马萨诸塞州通用医疗公司名义经营 预防和治疗烧伤损伤和继发性并发症的方法
WO2015060462A1 (en) * 2013-10-23 2015-04-30 Kaneka Corporation Tetrapeptide compound and method for producing same
CN104725472A (zh) * 2010-01-25 2015-06-24 康奈尔大学 芳香族阳离子肽及其用途
WO2016001042A1 (en) * 2014-06-30 2016-01-07 Flamma S.P.A. Process for the production of d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG64368A1 (en) 1988-06-30 1999-04-27 Astra Ab Dermorphin analogs their methods of preparation pharmaceutical compositions and methods of therapeutic treatment using the same
EP1599216B9 (en) 2003-02-04 2015-02-11 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
US20120178762A1 (en) * 2006-12-15 2012-07-12 Warner Chilcott Company, Llc Compositions of azimilide dihydrochloride
US8586598B2 (en) 2009-04-29 2013-11-19 Nerviano Medical Sciences S.R.L. CDK inhibitor salts
ES2964555T3 (es) 2009-08-24 2024-04-08 Stealth Biotherapeutics Inc Péptido para uso en la prevención o tratamiento de la degeneración macular
EP3090754A1 (en) * 2009-12-31 2016-11-09 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
EP3375449A1 (en) * 2010-03-15 2018-09-19 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
WO2011156473A1 (en) 2010-06-09 2011-12-15 Abbott Laboratories Crystalline forms of kinase inhibitors
CN104244964A (zh) * 2012-02-22 2014-12-24 康肽德生物医药技术有限公司 用于预防或治疗眼科病状的方法和组合物
ES2755134T3 (es) * 2013-03-01 2020-04-21 Stealth Biotherapeutics Corp Métodos para el tratamiento de enfermedad mitocondrial
WO2015084649A1 (en) 2013-12-03 2015-06-11 Amgen Inc. Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1 -phthalazinamine pharmaceutically acceptable salts and uses thereof
WO2016004067A1 (en) * 2014-06-30 2016-01-07 Stealth Biotherapeutics Corp Aromatic-cationic peptide formulations, compositions and methods of use
WO2016007921A1 (en) * 2014-07-10 2016-01-14 Rhodel Island Hospital Treating arrhythmia with mitochondrial-targeted antioxidants
EP3265109B1 (en) 2015-03-06 2020-10-21 Stealth BioTherapeutics Corp Processes for preparing pharmaceutically relevant peptides
CA3017359A1 (en) 2016-03-11 2017-09-14 Scott M. Duncan Crystalline salt forms
EP3500286A4 (en) * 2016-08-16 2020-03-25 Stealth BioTherapeutics Corp N-CARBOXYANHYDRIDE-BASED SCALE SYNTHESIS OF ELAMIPRETID
US11034724B2 (en) * 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
US10676506B2 (en) * 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
KR20250010134A (ko) * 2018-04-02 2025-01-20 스텔스 바이오테라퓨틱스 인코포레이티드 엘라미프레티드의 합성에 유용한 결정질 디펩티드

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103933542A (zh) * 2009-03-20 2014-07-23 通用医疗公司以马萨诸塞州通用医疗公司名义经营 预防和治疗烧伤损伤和继发性并发症的方法
CN104725472A (zh) * 2010-01-25 2015-06-24 康奈尔大学 芳香族阳离子肽及其用途
WO2015060462A1 (en) * 2013-10-23 2015-04-30 Kaneka Corporation Tetrapeptide compound and method for producing same
WO2016001042A1 (en) * 2014-06-30 2016-01-07 Flamma S.P.A. Process for the production of d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide

Also Published As

Publication number Publication date
EP3426675A1 (en) 2019-01-16
WO2017156403A1 (en) 2017-09-14
US20210047368A1 (en) 2021-02-18
EP3426675B1 (en) 2020-08-05
EP3426675A4 (en) 2019-10-16
US10683326B2 (en) 2020-06-16
US11555053B2 (en) 2023-01-17
CA3017359A1 (en) 2017-09-14
JP2019512542A (ja) 2019-05-16
US20260015385A1 (en) 2026-01-15
US12252553B2 (en) 2025-03-18
JP7038675B2 (ja) 2022-03-18
US20190382442A1 (en) 2019-12-19
US20230279049A1 (en) 2023-09-07
CN109476700A (zh) 2019-03-15

Similar Documents

Publication Publication Date Title
US12252553B2 (en) Crystalline salt forms
US11261213B2 (en) Crystalline bis- and tris-hydrochloride salt of elamipretide
CN103827122B (zh) 利福昔明的形式及其用途
US8513275B2 (en) Forms of rifaximin and uses thereof
GB2542881A (en) Crystal forms of ß-nicotinamide mononucleotide
US12466832B2 (en) Monohydrate and crystalline forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
TW200815344A (en) Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
TW201200511A (en) Crystalline salts of a potent HCV inhibitor
US11325943B2 (en) Crystalline salt forms of SBT-20
US11976074B1 (en) Crystalline salts of Linsitinib
TWI462915B (zh) 一種組織胺ｈ３受體拮抗劑的新穎富馬酸鹽
US20150239890A1 (en) Crystal of n-[2-(amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide
TWI314930B (en) Novel salt form of a dopamine agonist
HK40003395B (en) Crystalline salt forms
US10273206B2 (en) Tromethamine salt of bimatoprost acid in crystalline form 1, methods for preparation, and methods for use thereof
WO2022235726A1 (en) Solid forms of (r)-oxybutynin d-malate

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination